Pencil Beam Scanning in Patients With Renal Tumors
This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
Conditions:
🦠 Renal Tumor 🦠 Wilms Tumor
🗓️ Study Start (Actual) 26 December 2017
🗓️ Primary Completion (Estimated) 30 July 2025
✅ Study Completion (Estimated) 30 September 2025
👥 Enrollment (Estimated) 28
🔬 Study Type INTERVENTIONAL
📊 Phase EARLY_PHASE1
Locations:
📍 Philadelphia, Pennsylvania, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Less than 30 years of age
    • * Diagnosis
    • a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including
    • 1. Any patient with favorable histology (FH), stage III disease
    • 2. Any patient with focal or diffuse anaplasia
    • 3. Any patient with CCSK
    • * The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK

    Exclusion Criteria:

    • * Prior radiotherapy to the region of the study cancer
    • * Chemotherapy administered for diagnosis of Wilms tumor or CCSK
    • * Pregnant or breastfeeding
Ages Eligible for Study: 0 Years to 30 Years (CHILD, ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 15 January 2019
  • First Submitted that Met QC Criteria 17 January 2019
  • First Posted 22 January 2019

Study Record Updates

  • Last Update Submitted that Met QC Criteria 24 May 2024
  • Last Update Posted 28 May 2024
  • Last Verified May 2024